Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06865261

Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance

Effects of L-arginine and Liposomal Vitamin C Supplementation on Physical Performance and Endothelial Function in Elderly With Sarcopenia

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
All
Age
70 Years
Healthy volunteers
Not accepted

Summary

In older age, reduced mobility is associated with an increased risk of reduced quality of life, disability, institutionalisation, and death, as well as increased healthcare expenditures. Sarcopenia is a condition characterised by a reduction in muscle mass and strength and/or function. It is associated with several adverse outcomes, such as falls, increased risk of infection, disability, institutionalisation, and death. Currently, no pharmacological treatments are available to combat sarcopenia. The management of sarcopenia relies on the adoption of an active lifestyle, comprising resistance exercise, which may be supported by an adequate intake of protein with the diet. Recently, treatment with L-arginine and liposomal vitamin C has been shown to significantly reduce fatigue, and improve physical performance and endothelial reactivity in adult patients with Long COVID. Long COVID may be considered a model of accelerated ageing, as it recapitulates several age-associated biological processes, including chronic inflammation, oxidative stress, endothelial dysfunction and malnutrition.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTBioarginina CBioarginine®C oral vials is a dietary supplement based on L-arginine and liposomal Vitamin C that is useful for making an integrative share of L-arginine and Vitamin C. Liposomal Vitamin C is a particular type of Vitamin C produced through an innovative technology that optimizes and amplifies its absorption.
DIETARY_SUPPLEMENTPlaceboVials containing placebo were made to be indistinguishable in appearance from active treatment

Timeline

Start date
2024-05-20
Primary completion
2025-10-31
Completion
2025-12-31
First posted
2025-03-07
Last updated
2025-03-07

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06865261. Inclusion in this directory is not an endorsement.